Use of cangrelor for complex percutaneous coronary intervention in the context of concomitant severe aortic stenosis:
Francesco Soriano1, Andrea R Munafò1, Nurcan Baydaroglu1
1Interventional Cardiology, De Gasperis Cardio Center, Niguarda Hospital, Piazza Ospedale Maggiore 3, 20162 Milan, Italy.
European Heart Journal. Case Reports
|May 22, 2024
Summary
Cangrelor, a P2Y12 inhibitor, can minimize bleeding and thrombotic risks during transcatheter aortic valve implantation (TAVI) with percutaneous coronary intervention (PCI). This approach offers tailored platelet inhibition for complex procedures.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pharmacology
Background:
- Increasing need for combined transcatheter aortic valve implantation (TAVI) and percutaneous coronary intervention (PCI).
- Cangrelor offers rapid P2Y12 inhibition with short offset, potentially reducing complications.
- Large-bore arterial access (LBAA) in TAVI/PCI increases bleeding and vascular risks.


